MedTrace Logo

Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

NCT00745225 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2021-10-08

No results posted yet for this study

Summary

To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients

Conditions

  • End-stage Renal Disease

Interventions

DRUG

Pioglitazone

pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks

DRUG

placebo comparator

1 capsule daily, 96 weeks.

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Angela YM Wang, MD, PhD, FRCP · University of Hong Kong, Queen Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745225 on ClinicalTrials.gov